Scarica l'app Stockscreener
86.29
0.65%
0.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$85.73
Aprire:
$86.66
Volume 24 ore:
3.60M
Relative Volume:
0.90
Capitalizzazione di mercato:
$49.74B
Reddito:
$6.30B
Utile/perdita netta:
$1.07B
Rapporto P/E:
46.88
EPS:
1.8406
Flusso di cassa netto:
$1.09B
1 W Prestazione:
-2.23%
1M Prestazione:
-5.04%
6M Prestazione:
+4.38%
1 anno Prestazione:
+14.64%
Intervallo 1D:
$84.92
$87.11
Intervallo di 1 settimana:
$84.92
$89.66
Portata 52W:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27 - MarketBeat
Wall Street Zen Downgrades Edwards Lifesciences (NYSE:EW) to Hold - MarketBeat
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences $39M Securities Class Action Settlement - Claim Depot
EW IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class ActionEW - TMX Newsfile
Andra AP fonden Boosts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
Edwards Lifesciences stock up 726% in 15 years, beating market - scanx.trade
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions - Yahoo Finance
Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead - Yahoo Finance
Edwards Lifesciences stock heads into the open after a 4.1 percent jump - AD HOC NEWS
Is It Too Late to Buy Edwards Lifesciences Corp (EW) After 4.1% Rally? GF Value Says Undervalued - GuruFocus
Edwards Lifesciences Corporation's Stock Price Soars to $89.28, Marking a Strong 4.13% Increase - Smartkarma
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth - Investing.com
Bank of America Corp DE Takes $605.40 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock heads into the open after a mid-80 dollar close - AD HOC NEWS
California State Teachers Retirement System Buys 23,304 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
$100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today - Benzinga
Edwards Lifesciences Corp (EW) Stock Analysis: A Potential 19.67% Upside in the Healthcare Sector - DirectorsTalk Interviews
Edwards Lifesciences Insider Daniel Lippis Sells 619 Shares at $87.51 Following Option Exercise - Kalkine Media
Truist raises Edwards Lifesciences target to $95 - scanx.trade
Wall Street Zen Upgrades Edwards Lifesciences (NYSE:EW) to "Buy" - MarketBeat
Insider Daniel Lippis Sells 619 Shares of Edwards Lifesciences C - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock By Investing.com - Investing.com Australia
Why Edwards Lifesciences (EW) Stock Is Down Today - Quiver Quantitative
Edwards Lifesciences, Medtronic score CMS win for TAVR - MassDevice
CMS TAVR changes, a boon for Edwards - BioWorld News
Edwards Lifesciences stock price target maintained at $85 by Canaccord - Investing.com Canada
Engineers Gate Manager LP Sells 81,590 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Comments on TAVR National Coverage Decision - Finviz
Edwards Lifesciences maintains 2026 guidance after CMS TAVR NCD - scanx.trade
Edwards Lifesciences stock edges higher after raised 2026 revenue guidance - ad-hoc-news.de
Edwards Lifesciences stock heads into the open after a mild decline - ad-hoc-news.de
EW Stock Quote Price and Forecast - CNN
Can Edwards Lifesciences (NYSE:EW) Withstand Market Pressure? - Kalkine Media
Amundi Decreases Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock heads into the open after a 3.2 percent drop - ad-hoc-news.de
Edwards Lifesciences Corp (EW) Stock Down 3.5% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Edwards Lifesciences Stock Underperforming the Dow? - Yahoo Finance
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW) - Seeking Alpha
Azimuth Capital Investment Management LLC Decreases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
B. Metzler seel. Sohn & Co. AG Lowers Position in Edwards Lifesciences Corporation $EW - MarketBeat
EW Stock Price and Chart — NYSE:EW - TradingView
Nykredit A S Makes New $20.64 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit 2026 - BioSpace
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.70%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):